1 / 6

SAFC Press Briefing Informex 2012

SAFC Press Briefing Informex 2012. Gilles Cottier President of SAFC February 16, 2012. SAFC Results for 2011. • $728 Million in Sales • 9% Organic Growth • 2011 performance driven by our industrial media and Hitech sales, which both grew double digits. 2012 Highlights.

magar
Download Presentation

SAFC Press Briefing Informex 2012

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SAFC Press BriefingInformex 2012 Gilles Cottier President of SAFC February 16, 2012

  2. SAFC Results for 2011 • $728 Million in Sales • •9% Organic Growth • • 2011 performance driven by our industrial media and Hitech sales, which both grew double digits

  3. 2012 Highlights • Grow SAFC business in high single-digit by leveraging customer focus, unique manufacturing capabilities and adjacent services • SAFC Hitech plant in Taiwan on-line in Q1 2012

  4. BioReliance Overview 2010 Revenue by Segment Global biopharmaceutical services organization • Biologics Testing: global market leader for safety testing and support services for manufacturers of biologic therapeutics • Specialized Toxicology Studies: global market leader for genetic toxicology testing; leader in transgenic model studies for oncogenicity • Animal Health Services: broad spectrum of laboratory animal diagnostic and analytical services for health monitoring and disease outbreak Biologics Toxicology Animal Health Services 2010 Revenue: $110M Global Facilities Glasgow, Scotland Stirling, Scotland Tokyo, Japan Rockville, USA Bangalore, India Total Employees: ~650 BioReliance currently performs testing for ~75% of the top Pharma companies and ~90% of the top Biotech companies in the world.

  5. Strategic Context Combination creates one of the broadest product and services offerings for the development and manufacturing of biological drugs Benefits biopharmaceutical customers with a broad portfolio of product solutions and services Provides platform from which to expand across laboratory and biological services Financial Impact Purchase price approximately $350 in cash Expected to be accretive to growth rate and earnings in 2012 Opportunity to drive incremental revenue growth and returns over time through cross-selling, geographic expansion and expansion of technology platform BioReliance Strategic Rationale and Transaction Benefits

  6. Raw Material Manufacturing & Supply Complementary Biologic Development & Manufacturing Overview Upstream Bioprocessing Downstream Bioprocessing Lot Release & Downstream Process Testing Contract Biologic Manufacturing Raw Material Testing Research Cell Line Production Cell Line (“Cell Bank”) Unprocessed Bulk Product Final Drug Product Purified Bulk Drug Substance Bioreactor Cloning, cell selection & expansion Media development, upstream process optimization (“scale up”) Process Chromatography Formulation development, stability testing, fill & finish Expression System and Cell Line Development Upstream Process Development Legend: BioReliance Sigma-Aldrich/SAFC

More Related